enGene Holdings Inc. Common Stock

NasdaqCM ENGN

enGene Holdings Inc. Common Stock Price to Earnings Ratio (P/E) on February 05, 2025: -6.38

enGene Holdings Inc. Common Stock Price to Earnings Ratio (P/E) is -6.38 on February 05, 2025, a -81.02% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • enGene Holdings Inc. Common Stock 52-week high Price to Earnings Ratio (P/E) is -2.19 on August 20, 2024, which is 65.64% above the current Price to Earnings Ratio (P/E).
  • enGene Holdings Inc. Common Stock 52-week low Price to Earnings Ratio (P/E) is -8.04 on March 25, 2024, which is -26.11% below the current Price to Earnings Ratio (P/E).
  • enGene Holdings Inc. Common Stock average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.75.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
SV Wall Street
NasdaqCM: ENGN

enGene Holdings Inc. Common Stock

CEO Mr. Ronald H. W. Cooper
IPO Date Feb. 1, 2022
Location Canada
Headquarters 7171 Rue Frederick Banting
Employees 31
Sector Healthcare
Industries
Biotechnology
Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

StockViz Staff

February 6, 2025

Any question? Send us an email